- NYSE: MRK has reported robust earnings for the third quarter, driven by a cancer therapy.
- Broader markets have been on the back foot due to the surge in covid cases.
- After weathering the storm, Merck has room to rise.
Markets are focused on coronavirus, but other diseases still grip the world – and Merck & Co., Inc.(NYSE: MRK) is set to benefit once the storm subsides. Shares of the New Jersey-based pharmaceutical giant have been on the back foot, falling by 1% on Tuesday. This slide is in line with the broader S&P 500 and other indexes, which are grappling with the spread of COVID-19 in Europe – and also in the US. The seven-day rolling average has surpassed 70,000 cases in America.
Merck and Co has been out of the spotlight in recent months, as other firms stood out in racing for a covid vaccine or therapeutics. However, the company still reported an increase in drug sales, mostly driven by a lung cancer immunotherapy treatment called Keytruda. Income from this medication jumped by 21% to $3.7 billion, beating estimates.
Moreover, MRK has upgraded its forecasts, saying it now projects a full-year adjusted profit of $5.91-$6.01 per share, with the bottom end of the range surpassing the previous top of the range – $5.78. The earnings report should help Merck weather the current market storm and push its shares higher.
On the other hand, the elections pose a risk to the pharmaceutical sector. Democrats have high chances of winning not on the White House but also the Senate. A President Joe Biden and with dominant Senators such as Bernie Sanders and Elisabeth Warren could work to lower drug prices. While Dems' priorities are first and foremost fiscal stimulus, they could reform healthcare later on, potentially weighing on pharma firms.
MRK Stock Forecast
NYSE: MRK has been sliding in the past month, and seems to have reached critical support at around $78.
It hit the same level last week and an attempt to break above $80 failed for now. The round $75 level is the next one to watch on the downside. Above $80, the next upside target is $83.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
USD/JPY refreshes monthly high above 155.00 on BoJ's rates on-hold
USD/JPY is back above 155.00, refreshing monthly highs following the BoJ policy verdict. The BoJ left the short-term rate target unchanged in the range of 0.15%-0.25%. The decision came in line with the market expectations. Governor Ueda's press conference is now awaited.
AUD/USD bounces off two-year lows at 0.6200 as USD takes a breather
AUD/USD rebounds from two-year lows of 0.6200 early Thursday. The pair benefits from a pause in the hawkish Fed cut-led US Dollar uptrend. However, concerns about China's fragile economic recovery and Trump's tariff plans could cap the Aussie's recovery.
Gold sees a dead cat bounce following Fed’s hawkish cut
With the full final week of 2024 almost drawing to a close, Gold price remains vulnerable near one-month lows below $2,600, licking the hawkish US Federal Reserve policy decision-inflicted wounds.
Crypto market bleeds following hawkish rate cut decision by Fed
Bitcoin and the crypto market are down on Wednesday following the Federal Open Market Committee announcement to slow down rate cuts in 2025, with the benchmark federal funds rate declining to a lower range of 4.25% to 4.50%.
Sticky UK services inflation to come lower in 2025
Services inflation is stuck at 5% and will stay around there for the next few months. But further progress, helped by more benign annual rises in index-linked prices in April, should see ‘core services’ inflation fall materially in the spring.
Best Forex Brokers with Low Spreads
VERIFIED Low spreads are crucial for reducing trading costs. Explore top Forex brokers offering competitive spreads and high leverage. Compare options for EUR/USD, GBP/USD, USD/JPY, and Gold.